Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
October 31, 2024
Earnings Call Speaker Segments
Chris Taylor
executiveThanks, operator. Hello, everyone, and good morning. We're glad you could join Agios' conference call and webcast, where we'll go over the financial results for our third quarter of 2024 along with recent business highlights. Today's slides can be found if you visit the Investors section at agios.com. With me on this call are our Chief Executive Officer, Brian Goff; Dr. Sarah Gheuens, who serves as Chief Medical Officer and Head of R&D; Tsveta Milanova, our Chief Commercial Officer; and Cecilia Jones, our Chief Financial Officer. Prior to beginning, I want to remind all of you that certain statements made during this call will contain forward-looking statements. Due to a variety of risks, uncertainties and other factors, including those described in our most recent filings with the SEC and any future filings we may submit to the SEC, actual events and results may differ materially from what any forward-looking statements express or imply; and now I'll hand things over to Brian.
Brian Goff
executiveThanks, Chris. Good morning to all of you, and I appreciate you being here with us. At Agios, our purpose is to create and bring to patients transformative medications that improve and prolong the lives of those dealing with rare diseases. Our particular emphasis is on rare conditions that cause red blood cells to malfunction and be destroyed, such as pyruvate kinase deficiency, or PKD, thalassemia, sickle cell disease, and lower-risk myelodysplastic syndrome, or MDS. Since red blood cells make up more than 80% of the cells within the human body, enhancing red cell health is a key route toward better overall health for individuals. Mitapivat, our lead product and a pyruvate kinase activator, features a novel mechanism of action that enhances red blood cell metabolism and boosts the quantity of energy, or ATP, that is available to sustain red blood cell health. We take pride in having produced positive results in Phase III trials for PKD and thalassemia, and we are enthusiastic about what mitapivat could achieve for sickle cell disease. In addition to those data readouts and the ongoing advancement throughout our existing pipeline, I am pleased to verify today that Agios has obtained $1.1 billion in milestone payments after the FDA's August approval of vorasidenib, a product that began at Agios. These payments consist of a $905 million payment from Royalty Pharma tied to the vorasidenib royalty purchase agreement Agios announced in May 2024, plus a $200 million payment from Servier related to Agios' 2021 divestiture of its oncology business. With the positive Phase III data readouts for mitapivat in thalassemia achieved this year and the recently announced completion of full enrollment in the Phase III RISE UP sickle cell disease study, we intend to use this robust cash position to get ready for potential mitapivat launches in thalassemia during 2025 and in sickle cell disease during 2026. Alongside this major influx of capital, we also achieved meaningful progress throughout our advancing clinical pipeline. First, we reported top line data from the Phase III ACTIVATE-KidsT study of mitapivat in children with PK deficiency who were regularly transfused, marking our first pediatric study of mitapivat. And second, we reached 2 milestones in our clinical development program for lower risk MDS; we announced that the FDA has granted orphan drug designation to tebapivat, our potent PK activator previously called AG-946, for treating myelodysplastic syndromes, or MDS. And we have started enrollment and begun dosing patients in the Phase IIb study of tebapivat in lower risk MDS, a space with substantial unmet need and considerable market growth. Crucially, as we finish out a highly productive and successful 2024, we remain on track to hit our key remaining milestone for this year, submitting an sNDA for mitapivat in thalassemia by year's end, seeking a broad label that covers adults living with all subtypes of thalassemia. Sarah will give a thorough update on our progress and forthcoming milestones across R&D in just a few minutes. Building on the encouraging results we saw in the Phase III ENERGIZE and ENERGIZE-T trials of mitapivat, our commercial team, which keeps growing, is getting ready in earnest for a possible U.S. launch of mitapivat for thalassemia during 2025. In a little while, Tsveta will walk through the thalassemia market opportunity in more depth, along with how thoroughly the team has prepared, plus a status update on the PKD launch we have underway right now. And as Cecilia will tell you, we closed out the third quarter sitting in a very solid cash spot, holding roughly $1.7 billion in cash and investments on the balance sheet — a figure that takes in the $1.1 billion of milestone payments that came our way after the FDA approved vorasidenib. Before I pass things to Sarah, I'd like to stress just how enormously proud we feel about everything accomplished so far in 2024, how sharply we're staying focused on closing out the year from a position of strength, and how excited we are about making further headway in 2025 and past that. So with that, I'll hand the call to Sarah now.
Sarah Gheuens
executiveThank you, Brian. Not long ago, we had the chance to take part in 2 important gatherings where our dialogue with the community carried on. Both at the Academy for Sickle Cell and Thalassemia Conference and the SCDAA annual convention, we received another reminder of how arduous the path is for those living with sickle cell disease. That strengthens our resolve regarding what we intend to offer these patients. Now, on sickle cell disease, the recent developments affecting this community have left us deeply saddened, and we remain unwavering in our pledge to provide a novel oral therapy that could potentially enhance anemia, VOCs, and how patients feel and function, especially when it comes to fatigue. Because of the encouraging data from the Phase II portion of the RISE UP study, along with favorable results we have seen in other hemolytic anemia sharing a common pathophysiology, we are enthusiastic about mitapivat's prospects of becoming a convenient first-in-class and best-in-class option that boosts red blood cell health for people living with sickle cell disease. As was shared last week, we are delighted to have reached our objective of finishing enrollment in the Phase III RISE UP study before the year ended, only slightly more than a year since we started recruiting this cohort. To recap, the Phase III study has a planned sample size of 198 subjects randomized 2:1 to mitapivat versus placebo across roughly 100 trial sites globally. Two primary endpoints exist: hemoglobin response, defined as a rise of no less than 1 gram per deciliter in average hemoglobin concentrations over weeks 24 to 52 compared with baseline, and annualized rate of sickle cell pain crises. Fueled by a differentiated mechanism of action, we believe mitapivat could tackle the significant unmet need in this disease by enhancing anemia, lowering sickle cell pain crises, and helping patients feel better; we anticipate reporting top line data from the Phase III next year; regarding thalassemia, our goal is to deliver the first therapy approved for all thalassemia subtypes. Given the encouraging data from both the Phase III ENERGIZE study of mitapivat in adults with non-transfusion-dependent alpha or beta thalassemia, and the Phase III ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha or beta thalassemia, we believe mitapivat may become a foundational and convenient oral treatment option for every subtype of thalassemia, covering all genotypes and all levels of transfusion burden. We are working diligently to advance the filing and still expect to submit an sNDA before this year ends, seeking a label that includes adults living with all subtypes of thalassemia. In pediatric PK deficiency, we were happy to announce top line data from the Phase 3 ACTIVATE-KidsT study of mitapivat in children with PK deficiency, who are regularly transfused. This trial is one we feel great about, for a couple of reasons. First off, it's the initial Phase III research effort to share results for this patient group, and even more significantly, it represents Agios's first pediatric study of mitapivat to reach completion. Although the predefined statistical threshold for the main endpoint wasn't reached, we view the findings as carrying real clinical weight, since so many patients showed a transfusion reduction response — among them individuals with a transfusion-free response, meaning they needed no red blood cell transfusions at all, plus those who hit a normal hemoglobin response, which we define as hemoglobin levels falling within normal limits on at least 1 occasion at 8 weeks or later following a transfusion. And secondly, the safety data for mitapivat lined up with what has previously been seen in adults who have PK deficiency and receive regular transfusions. Now that enrollment has wrapped up in the Phase III ACTIVATE-Kids trial, we're anticipating a data readout next year. Alongside the headway we keep making throughout the mitapivat development program, during this quarter we also achieved key strides in our tebapivat program. To start, we launched the Phase II trial of tebapivat in lower-risk MDS; this open label study is set to enroll 60 people in total who have transfusion-dependent lower risk MDS, testing 3 dose levels — 10 milligrams, 15 milligrams and 20 milligrams — all of which exceed the 5-milligram dose studied in the earlier Phase IIa trial. Enrollment for each dose level cohort will open one after another, with no breaks in between, so we'll begin by enrolling 20 patients at the 10-milligram dose, and after those spots are taken, we'll move on to enrolling 20 patients at the 15-milligram dose, then follow the same approach for the third cohort of 20 patients at the 20-milligram dose. Every cohort has a 24-week core period, which is then followed by a 156-week extension period. Transfusion independence will serve as the primary endpoint of this study, defined as going without a transfusion for a minimum of 8 consecutive weeks within the core period. Safety, change in hemoglobin and other measures of anemia will make up the secondary endpoints. Much like thalassemia, through this program we're aiming to bring forward the first oral therapy that tackles anemia caused by ineffective erythropoiesis in lower-risk MDS, a condition affecting roughly 75,000 to 80,000 patients throughout the U.S. and EU5 and representing about 70% of all MDS cases. During this quarter as well, we were thrilled to obtain FDA orphan drug designation for tebapivat in treating MDS; that highlights how vital it is to deliver new oral treatment choices to patients dealing with this rare disease, and we plan to share additional milestone timelines once enrollment has progressed further. As we look ahead, we're eager to take part in the upcoming annual meeting of the American Society of Hematology, ASH, and we anticipate accepted abstracts being published on November 5. With that, I'll hand the call over to Tsveta.
Tsveta Milanova
executiveAppreciate that, Sarah. As we prepare for a potential thalassemia launch, we're reminded how big the unmet need is in this disease, and also what value PYRUKYND might bring to thalassemia patients in every subtype; we continue to confirm that through the strong patient connections we build at conferences like ASCAT and at local community meetings held at selected patient centers. Thalassemia is much more common than PK deficiency, with about 6,000 adults diagnosed in the U.S., and roughly 4,000 of them are non-transfusion-dependent. The diagnosis rate for thalassemia is high, with many patients diagnosed before adulthood. Since we can access claims information and ICD-10 codes, we know who these patients are within the health care system, and that provides valuable clarity as we get ready for launch. Few treatment choices exist, particularly for those whose disease does not require transfusions, and most of them depend on supportive care. Every type of thalassemia carries elevated rates of serious morbidities, worse quality of life, and a greater chance of dying prematurely. The burden of disease is high, and the cost of care tied to it is substantial. Encouraged by the positive results from the ENERGIZE and ENERGIZE-T studies, our commercial team is actively getting ready to meet this high unmet need, with a possible U.S. launch of PYRUKYND in thalassemia next year. We have a lot of excitement around what PYRUKYND could mean as a first-ever approved treatment covering every thalassemia subtype. Progress keeps happening on our side in 4 launch readiness workstreams. To start, we're carrying out broad market studies along with claims data-driven reviews so that our understanding of the market gets sharper and our launch targeting and execution get better informed. From the effort completed so far, our estimate is that roughly 65% of adults living with thalassemia will be covered by where PYRUKYND is initially aimed at launch. Those patients already seeing the health care system on a routine basis because of their disease symptoms are the ones we anticipate being looked at for treatment first. The groups we're talking about here are made up of people who need regular transfusions, plus those who don't require transfusions but are already dealing with complications or coping with severe exhaustion. Members of our team are out in the field right now, building a deeper understanding of these various patient groups and the many cultural backgrounds within thalassemia. Next, our education efforts about the disease itself have centered on three things. One, we're bringing attention to how the disease works biologically, which involves ineffective erythropoiesis and hemolysis. Two, we feel it matters that both patients and doctors grasp the lasting complications and the overall burden this disease places on people across every thalassemia subtype — especially those with the non-transfusion-dependent form, since they wrongly believe their risk is lower. Third, through our ongoing conversations with patients and doctors alike, we emphasize how crucial it is to monitor and manage the disease regularly, which allows care plans to be customized to each person's specific requirements. Tying all of this together, we're happy to present one more illustration of the impactful Rethink Thalassemia campaign that we've introduced over the past several months. Its eye-catching visual and title draw viewers in to read more closely the text that illustrates thalassemia's concealed dangers. Feedback on this campaign has been highly positive, coming from both the patient and physician communities. They point out that the disease education content strikes them as both pertinent and worthwhile, not just for grasping the pathophysiology of the disease and its complications, but also for tying that understanding to why continuous monitoring and management matter. The third thing we're concentrating on as we get ready for launch is expanding our commercial and medical teams in a disciplined way, so the organization is sized appropriately to support a successful launch in what remains a rare market even though it is bigger. We keep steadily growing the team and bringing on added capabilities as we move toward a possible launch, with a sharp emphasis on remaining as capital-efficient as we can. And fourth, our market access group is already in discussions with payers about disease state education. I take pride in the wide access our team has obtained for PYRUKYND in PK deficiency, and our goal is to achieve that same strong result in thalassemia. Beyond the U.S., roughly 70,000 thalassemia patients live in the Gulf Cooperation Council, or GCC, region, and several of the foremost treatment centers there took part in our clinical trials. As we told you last quarter, we're happy to have signed a distribution agreement with NewBridge Pharmaceuticals in preparation for possible commercialization of PYRUKYND in the GCC region. We're also happy to share that PYRUKYND received breakthrough medicine status for thalassemia, which came from the Saudi FDA, also known as SFDA. Working closely with NewBridge, we're putting active effort into shaping the strongest regulatory and commercial strategy across the GCC region. Keep in mind that gaining access in any GCC nation generally begins with a price set at the regulatory stage, after which discussions move forward with health authorities, local institutions and the private sector. We're looking forward to handling each of those elements together with NewBridge. I'll now provide a brief update regarding the continuing PYRUKYND launch in PK deficiency. In Q3 2024, net revenue for PYRUKYND reached $9 million, compared with $8.6 million during Q2 2024. In the U.S., a total of 211 patients have finished a prescription enrollment form, including 10 in Q3 2024, marking a 5% increase versus the prior quarter. As a result, 127 net patients are now receiving therapy. We think the skills we continue to strengthen through this launch will provide a strong base for getting the most out of potential upcoming U.S. launches of PYRUKYND—for thalassemia in 2025 and sickle cell disease in 2026. In closing, the possibility of bringing a novel treatment to these patient groups around the globe who lack adequate options leaves us genuinely motivated and excited. At this point, I'll pass things along to Cecilia.
Cecilia Jones
executiveAppreciate that, Tsveta. You can find our third quarter 2024 financial results in this morning's press release, and our 10-Q, which gets filed later today, will carry more detail. So let me spend a moment giving some context and calling out a handful of key items. Net PYRUKYND revenue for the third quarter of 2024 came in at $9 million, which is 22% higher than the third quarter of 2023. As with other rare disease launches, gross-to-net has been running, and should continue to run, between 10% and 20% on an annual basis. Looking ahead, in line with the strategic shift we've made toward getting ready for a potential launch in thalassemia, we expect PKD revenues to show muted growth along with quarter-over-quarter variability, consistent with recent quarters. Cost of sales for the quarter totaled $0.8 million. R&D expenses for the third quarter were $72.5 million, down $9.4 million versus the third quarter of 2023; that decline was mainly the result of the $17.5 million upfront payment tied to the license agreement with Alnylam, which hit the prior year. SG&A expenses came to $38.5 million for the third quarter, up $12.7 million from the prior year quarter. The main driver there was growth in commercial-related activities as we get ready for a potential approval of PYRUKYND in thalassemia in 2025. Importantly, during this quarter we collected a total of $1.1 billion in milestone payments after the FDA approved vorasidenib. Those payments consist of $905 million from Royalty Pharma tied to the vorasidenib royalty purchase agreement Agios announced in May 2024, plus $200 million from Servier tied to Agios' divestiture of its oncology business in 2021, and both were recorded under other income in the P&L. As a reminder, Agios keeps a 3% royalty on annual U.S. net sales of vorasidenib above $1 billion. Counting those milestone payments, we closed the quarter with cash, cash equivalents and marketable securities of roughly $1.7 billion. We believe this balance, along with anticipated product revenue and interest income, gives us the financial independence to prepare for potential PYRUKYND launches in thalassemia and sickle cell disease, move existing programs forward and expand our pipeline opportunistically through assets discovered both internally and externally. We stay focused on creating shareholder value, including by proactively managing our cost base and taking a disciplined approach to cash allocation as we prepare to support potential future launches of PYRUKYND. With additional potential value-creating milestones coming up in the near term, I'm confident our balance sheet will keep letting us execute from a position of strength. I'll hand the call back to Brian now.
Brian Goff
executiveThank you, Cecilia. Ahead of taking questions, I'd like to wrap up with some closing remarks. Agios made remarkable strides during 2024; our major objectives keep being met, and our finances remain quite robust, which lets us carry this excellent momentum through the rest of this year and afterward. Beyond the approved PKD indication, mitapivat offers a major chance to substantially raise the care standard for thalassemia and sickle cell disease patients. Time and again, we hear directly from those communities that they urgently need novel treatment approaches for these conditions. Given that, mitapivat should become a first and best-in-class therapeutic choice across several indications, which makes it a franchise capable of generating billions of dollars. Alongside mitapivat, we keep advancing our other encouraging clinical efforts, zeroing in on places with substantial patient need and giving us further chances to build considerable long-term worth and impact for every stakeholder; we anticipate what lies ahead as we work to alter the course of these rare diseases. So, I'd now like to invite questions. Operator, kindly open the line.
Greg Harrison
analystWonderful to see how much has been accomplished. I have a couple of questions. To start, with vorasidenib now mostly turned into revenue, what's your thinking on allocating capital and your willingness to pursue business development? Is there perhaps a specific space that you find appealing or that fits well alongside what you have? Then, regarding sickle cell, could you share what you expect from the Phase III part of the study? And would you be able to discuss statistical power as it relates to VOC?
Brian Goff
executiveAbsolutely. Also, Greg, it's good to have you back. A pleasure to hear from you once more.
Greg Harrison
analystGood to be with you all.
Brian Goff
executiveThere are two pieces to this. Cecilia is able to address the question about allocating capital, and after that Sarah will pick things up regarding what we expect from RISE UP Phase III.
Cecilia Jones
executiveOkay, thank you, Greg. When it comes to allocating capital, we are certainly quite proud of the solid financial position we hold at present. As for the way we approach this, our top priorities will naturally be the possible launches for thal and, we hope, sickle cell afterward, while we keep pushing our pipeline forward — you'll be hearing more about MDS later today as well. Beyond that, we aim to grow that pipeline, whether through internal efforts and/or external ones. We remain fairly disciplined, and the quantity of cash sitting on our balance sheet does not alter that approach; we evaluate opportunities using the same standards we've applied before — meaning rare, transformative, possessing a clear regulatory path, and clearly generating value for our shareholders. So that has not shifted; we keep examining things that way. Across various areas, we've stated that we hold no preference regarding modality, and we'll continue exploring how we wish to broaden that.
Brian Goff
executiveBefore I hand things over to Sarah, I want to say upfront that I couldn't be prouder of her and the whole team for the remarkable, steady excellence they keep delivering. We felt genuinely good about being able to share, ahead of today's call, that enrollment for the Phase III trial of RISE UP is now fully complete, and if you've been following along, roughly 12 months have passed. I believe that speaks volumes about the profile and about how much confidence the community places in us, and once more, and this matters greatly, about the team's executional excellence. So, Sarah, does that work as an introduction?
Sarah Gheuens
executiveAppreciate that, Brian. And thanks for raising it. We're extremely proud of what the RISE UP team has done. Full enrollment was achieved — that had been one of the goals we set for this year — so that has us thrilled, and now our focus is on completing the study and bringing it through to the finish. As for what we expect from Phase III: it runs 1 year. There are 2 primary endpoints, which you're already aware of. The first is hemoglobin response. The second is reduction in sickle cell pain crises. The aim, naturally, is to provide a therapy capable of addressing sickle cell disease in its entirety — that means improvements in both hemolytic anemia and vaso-occlusion. Each endpoint carries 90% power or a bit above, so that the difference can be detected. We're quite enthusiastic about this and eager to reach the conclusion of the trial.
Alex Nackenoff
analystThis is Alex sitting in for Danielle. One more question regarding RISE UP. Would you mind discussing the primary endpoints for the RISE UP trial a bit? Do you believe you have to succeed on both endpoints? Or would a win on only one of them be enough to back a regulatory submission? For instance, might it be enough for a regulatory submission if you succeed on hemoglobin response along with a secondary clinical endpoint such as fatigue?
Sarah Gheuens
executiveThanks for asking that. So indeed, there are 2 primary endpoints — one is hemoglobin, which I referred to earlier, and the second one centers on VOCs. The reason we selected 2 primary endpoints is that together they can give useful insight into the disease as a whole. Thus, if we were unable to succeed on a single endpoint and only succeeded on the remaining one, we would still have a chance to shift alpha over to testing of secondary endpoints, letting us examine clinical benefit further. Fatigue is in fact one of those endpoints. Across the various hemolytic anemias we have investigated, we always aim with our drug to provide the hemoglobin plus narrative — that is, we better the hemolytic anemia while also attempting to succeed on feel and function. As you're aware, we managed to provide that in PKD and thalassemia, underscoring a fatigue improvement. Our thalassemia data additionally underscored that an improvement occurred in the 6-minute walk test; therefore our RISE UP study is structured similarly, so as to offer several routes by which we can address clinical benefit for sickle cell disease patients. As for what regulatory approval requires, that is for the regulators to examine the clinical trial data at the end of the package. Naturally, when we submit, we always — we hold the view that a benefit-risk profile exists that backs approval, yet in the end it is the regulators who perform the review and make the call on approval.
Brian Goff
executiveI want to jump in here, and again, this isn't only about how well we execute — it's also about the scientific know-how the team brings. Everything Sarah just walked everyone through had already been laid out in a poster back in 2021. Put another way, the design stayed the same. It was built this way right from day 1.
Sarah Gheuens
executiveCorrect.
Brian Goff
executiveAnd that matters a great deal, especially given how things have recently changed in sickle cell disease with other treatment choices; plus it makes us quite proud that starting on day 1, our design was meant to be what's called a hemoglobin plus design.
Gregory Renza
analystNice work on the progress. Brian, you talked about the confidence you've built up with the community when it comes to how you're executing and the benefit you're delivering through the mitapivat development program in sickle cell. I'd like to know whether you could speak to the broader reaction, and the chance that the community might lose faith given the Oxbryta pull and the events you mentioned. What is Agios doing to at minimum monitor that, pick up on it and kind of work it into how you move forward with the trial, plus the way you're reaching patients? And then as a second thing, have you had any dialogue or do you intend to with regulators regarding the possible dangers that have kind of been flagged around conducting trials at the Africa site? Congrats.
Brian Goff
executiveYeah. Many thanks, Greg; that's a significant question you're raising, since the sickle cell disease community has, I believe, as nobody would find surprising, endured a great deal. Treatment choices have always been scarce, and the wider community has definitely been through a path of medicines being on the market and then off it in particular areas, and that's genuinely difficult; and one illustration of our approach is that Sarah, myself and other colleagues from the team recently went to the Annual Sickle Cell Disease Association of America meeting in Atlanta. And that gave us an opportunity to listen, above all, and take in what's weighing on them, what worries them, how they view future treatment choices. And once more, to repeat something I take great pride in, we have consistently sought to stay closely connected with the community. And one illustration of that stretches back to the moment we put the RISE UP trial together, when we quite intentionally brought in people from the sickle cell warrior community. And what they contributed wasn't limited to the trial design, the inclusion and exclusion criteria, but crucially, the right way to enroll for the trial. And by now you've witnessed what came of it; enrollment went extremely well. And afterward, hopefully, once we reach the commercialization stage, we're drawing on that community to steer us there too. So I'd say the key point regarding trust is that we aim to be highly visible. We listen. We listen free of bias and we ensure the community can see their own imprint on our work, reflecting what they've told us.
Sarah Gheuens
executiveYes, and building on that point about how the trial moves forward — we're keeping it going, and since this is a Phase III study, we obviously monitor the data continuously as it comes in. We follow all of our usual procedures to ensure we keep executing this trial well, and we'll keep watching closely as it progresses. As for the potential risk tied to sickle cell disease, particularly when you're conducting clinical trials, it's a difficult and devastating condition where patients deal with a huge number of comorbidities, and it can be fatal. So running a trial like this always brings challenges, but that reflects the unmet need within this patient population. So even though these trials are hard and challenging, the unmet need in this patient group is so great that we truly hope to deliver a drug that can be meaningful for the patient community and address the disease in its totality.
Brian Goff
executiveTo really make this clear, I want to add one more thing: Sarah and I spoke with people from the sickle cell disease warrior community—specifically, some members of that advocacy group I mentioned earlier. That call included 7 people from the community. Of those, 3 were currently in crisis or had gone through one not long before. We came away with a sobering reminder of how severe this disease truly is, and how urgently the community needs new therapeutic options—and that should be plural. We always celebrate progress from anyone, since this is a condition that requires multiple options.
Eric Schmidt
analystStaying on the subject of Oxbryta being pulled, which happened roughly a month back, I'm curious what you've gathered scientifically, or what your scientific thinking is, regarding how that drug works and whether that has any connection — or no connection — to mitapivat, and how it might affect your odds of succeeding in the study that's still running?
Sarah Gheuens
executiveThanks for raising that. As you're aware, Oxbryta's mechanism is quite distinct, and honestly — let me begin by saying we feel genuinely saddened by what took place. To echo Brian's earlier remark, it's a tragic situation, since this patient population truly has almost no choices available. So it's upsetting to witness. Its mechanism is really quite different. The trials were also designed in a different way; so I'd say that's — we aren't aware of anything beyond what's been made public; but turning to our own trial, our compound acts in a very distinct manner and takes that multimodal strategy toward treating — potentially treating sickle cell disease; so we do bring down 2, 3-DPG while raising ATP, and our view is that these two elements can interact and matter for preventing sickling as well as bettering hemolysis, and through that the anemia side of things. So the mechanism differs greatly from Oxbryta's, which naturally also shows up in the clinical data gathered thus far, with a Phase II dataset that proved very robust, a placebo-controlled study, and that mechanism has carried through to us showing a hemoglobin improvement and additionally seeing that favorable trend in hemolysis and VOC reduction. So we're eager to keep moving this — the drug ahead into Phase III.
Chris Raymond
analystNice work, everyone. I might have one more thing to ask about what's going on with Oxbryta. I realize you mentioned working with the sickle cell patient community. Still, this keeps coming up from investors, and I don't know whether anyone has a solid response. Do you have any idea how the regulatory view has shifted here? Some people argue things may have gotten stricter, while others say it might actually have gotten easier when it comes to another treatment being available on the market. Any thoughts on how the regulators could be responding to all this?
Sarah Gheuens
executiveYeah. And I believe — well, thank you for raising that, since I think Brian actually brought it up, with the poster we showed back in 2021, which was a Phase III trial design. Right from the start, our clinical development strategy and our regulatory strategy were quite different from the path Oxbryta took. So Oxbryta received accelerated approval by showing hemoglobin improvement when it was submitted, and then there were follow-up studies to show further clinical benefits. Our aim from — when we initially put this trial together was to provide a treatment that by the end of the trial could demonstrate clinically meaningful benefit, which means hemoglobin plus a reduction in sickle cell pain crises; so given what happened, we haven't altered our clinical design approach or how we deal with regulators. Like I said before, with any data package you send in, it's always a back-and-forth with the regulators once they go through the first package, and then they'll come back with additional questions. And in the end, they're the ones who determine the final benefit-risk.
Tessa Romero
analystLet's pivot for a moment to thalassemia. This morning you laid out in your slide deck a number of patient groups that fall within your initial launch focus for PYRUKYND. Could you give us somewhat more granular quantitative specifics on how the epidemiology splits out when it comes to patient counts within each of those 3 main target populations you referenced? And within those same 3 key groups, what's the typical frequency with which these patients visit their health care provider?
Brian Goff
executiveThank you, Tessa. Let me begin by noting that you've got Tsveta grinning over here, since questions about sickle cell disease are ones we adore. The opportunity we see with a possible launch scenario in 2026 has us quite thrilled, yet thalassemia sits even nearer on the horizon — there we've said all along that a potential launch in 2025 is something we're eagerly anticipating. With that, I'll hand things to Tsveta to address your questions.
Tsveta Milanova
executiveSure thing. Thank you, Tess, for asking. We're really enthusiastic about the possibility of securing approval for thalassemia in the coming year, and we're getting ready for launch in an active way. Thinking about thalassemia, honestly, it's a specific indication. From a commercialization standpoint, it's an attractive, uncommon disease indication for three primary reasons. The first is that we're aware of 6,000 adults in the U.S. who carry a thalassemia diagnosis, and I want to stress diagnosed here, since these individuals are recognized and involved with the health care system. We're confident of that because ICD-10 codes exist, and that lets us roll out our resources in an effective and efficient manner for launch preparation. We've discussed sickle cell disease and its substantial unmet need at length, yet that holds equally, very much so, for thalassemia too. The unmet need is understood, and we keep working with both patients and physicians through our prelaunch efforts to keep teaching them about the disease burden. As for which patients get prioritized for our initial launch focus, as you noted, we think roughly 65% of those 6,000 patients will be our target for the initial launch. Those patients fall into 3 groups. They are individuals who are highly involved with the health care system. The first consists of transfusion-dependent patients, who go often for transfusions and maintain contact with their hematologists. That's tied to how frequently they get transfusions, but roughly speaking, their interaction and involvement with the health care system is likely each month. The second group is made up of non-transfusion-dependent patients who have already developed comorbidities. They need regular monitoring and management. That varies with the particular patient population and how often, but we know from claims data as well as our initial account profiling that these patients are seen fairly routinely, and they'll be evaluated for management and continued monitoring too. And the third portion of the patient population, which makes up that 65%, is non-transfusion-dependent patients dealing with debilitating fatigue. It affects their everyday life, and they'll be looking for a possible treatment option too; we haven't given specific details about this patient population, but as the launch moves forward, we'll share additional information as well.
Brian Goff
executiveAlso, let me mention this: Tsveta, given all she has done in rare disease launches, is always the one reminding everyone that "launch" can be a strange word to use, since it isn't a single moment but rather something ongoing. So even with this guidance and the sequencing, if we were able to frame it that way with those segments, we'll keep going. And Tsveta works nonstop to keep the team out in front of segment 1, segment 2, and so forth. And we anticipate making progress over the long term in thalassemia and then, we hope, in sickle cell disease too.
Divya Rao
analystDivya here, filling in for Mark. First, staying with thalassemia, could you share your thinking on when the pediatric trials would start and how they'd be designed, given that we now have at least the initial data, or the top line data, from the Kids trial in PKD? And our second question concerns the initial tebapivat data in MDS, which clearly showed a bit of signal, though it was fairly modest at the 5-mg dose. Could you discuss what you view as the bar for success for the Phase IIb, now that you're evaluating dose levels above the initial dose tested?
Sarah Gheuens
executiveThanks, Divya. Regarding thalassemia, the pediatric trials — yes, we are indeed very proud of the first PKD pediatric trial, where we managed to show that some children achieved transfusion independence. So that's very pleasing for us to see, since it's clearly clinically meaningful. As for the timing and design of the trial, we now also have the benefit-risk profile in the adult thalassemia population. So you can expect us to take an approach similar to the one we took for PKD. We haven't provided further detail on when we would begin, so more to come at a later time point. On MDS, yes, we did meet our pre-specified criterion for the Phase IIa, where we saw 40% transfusion independence among the patient population we enrolled. And as you noted, we learned there that PK in MDS patients differed from what we'd seen in healthy volunteers. That, of course, drove changes for our Phase IIb. And as you can see, we have now moved ahead with the Phase IIb, testing higher doses — 3 higher doses — to hopefully strengthen the observations we made, and we're focused on transfusion independence in that trial, and 8-week or more transfusion independence, based on clinical advisory feedback we received. So we're excited to move that trial forward, and more to come.
Brian Goff
executiveWe see a lot of promise here in MDS, and that has all of us quite enthusiastic. I realize people watch what other companies in this space are doing, and this morning we observed how Reblozyl keeps advancing — that market is expanding quickly. The unmet need remains extremely high; in some respects it resembles sickle cell disease, where having several therapeutic choices is what will ultimately solve the problem. We also take real pride in having a mechanism that stands apart, so getting the Phase IIb underway marks a meaningful milestone for us.
Alec Stranahan
analystI've got a couple of things. To begin with, regarding preparations for the thalassemia launch, since it's a continuum, as Brian mentioned, I'm curious whether you have any insight into how soon payer access might become available? Also, would you say payers have a solid grasp of mitapivat's clinical profile and the unmet need it addresses, or is there still more work to be done there? Then, about the forthcoming full readout for ENERGIZE-T, should we anticipate any further efficacy data from that readout beyond what the top line already showed? Where do you think people's attention should be focused in the next update? And ASH seems like the next most probable venue, correct?
Brian Goff
executiveThank you, Alec; so Tsveta can begin with the question about the payers and the thalassemia launch, and then Sarah can take over with ENERGIZE-T.
Tsveta Milanova
executiveSure, Alec — I appreciate that, and it's a really pertinent thing to ask. Looking at it through a payer lens, as I think the slides and what we shared today make clear, market access stands as a central pillar of how we're getting ready to launch. Our market access group is out there right now talking with payers about educating them on the disease state. If you consider thalassemia and view it through the eyes of a payer, it's a rare condition. Awareness of it tends to be fairly limited, so we're certainly doing education about the disease. The upside, though, is that because it's rare, we don't anticipate it ranking high on payers' lists when it comes to management either. So the team is getting set for launch. I have to say our access work in PK deficiency produced a fantastic result; we have a really capable team, and going forward with thalassemia we expect to keep seeing that same level of achievement and momentum.
Brian Goff
executiveGreat. Then, Sarah, could you speak to ENERGIZE-T?
Sarah Gheuens
executiveSure. Regarding ENERGIZE-T, as we stated in our press release, we've announced our primary endpoint along with one secondary endpoint; so what you can anticipate from us is consistent with how we handle every Phase III readout, with intent to treat analysis and specifics on key secondary endpoints, plus the safety overview. In fact, we're hoping to present at a medical meeting in the near future. ASH isn't open at the moment; abstracts will come out on November 5; so we're also eagerly awaiting that.
Lydia Erdman
analystThis is Lydia sitting in for Salveen. Congratulations on everything you've accomplished. We've just got a couple of quick questions. First, regarding sickle cell, since you've now finished enrolling patients, can you share anything about how many baseline VOCs there were? Then, about tebapivat, could you talk about your timeline for releasing Phase IIb data? And please remind us what that update will cover.
Sarah Gheuens
executiveWhen it comes to sickle cell disease, baseline characteristics aren't something we present. Our usual approach is to share everything at the point we announce top line results. So there won't be anything released prior to the complete data readout. As for tebapivat and the Phase IIb, we've clearly now hit our corporate milestone for this year. So next year, we look forward to giving more specifics and timing regarding the remainder of the trial.
Andrew Berens
analystI have a couple of questions. Regarding 946, my understanding is that in the Phase IIa trial, some patients received doses above 5 milligrams. If I've got that right, how might we expect to see those results shared? Also, could you refresh my memory on how much room you believe exists for increasing the dose before a DLT could occur? Then, I believe this came up briefly, but we've been hearing about an issue involving sepsis and malaria at the African trial sites, and a number of investors believe it was tied to how those sites were run. My understanding is that your trial includes some of those same sites; could you shed some light on the steps being taken so that a similar issue won't happen?
Brian Goff
executiveThank you, Andy. I'll hand things over to Sarah, but before that I wanted to mention that when you referred to 946, we're making an effort on our side to call it tebapivat; we're quite proud of the new INN we've received for our second, more potent PK activator. And Sarah, would you like to begin with the IIa?
Sarah Gheuens
executiveTherefore, in the Phase IIa trial, only the 5-milligram dose was examined; as a result, we didn't evaluate larger doses during that IIa study. At present, the greater doses under investigation belong to the IIb segment of the trial, specifically 10, 15, and 20 milligrams. As for when I anticipate reaching the DLT, I cannot say, since we have not yet collected those data. Thus, information will build up gradually, and after that we will determine whether we see anything that discourages us from continuing to study a particular dose. So there is more to come regarding that; concerning your question about mitapivat along with sepsis and malaria seen in the Oxbryta trials, malaria occurs naturally in specific parts of the globe. Some of our R&D trials are also run in Africa, yet we have an excellent geographic spread overall within RISE UP. That makes us enthusiastic. The findings that have occurred with Oxbryta are not findings that have occurred with hydroxyurea, for example, that have been noted in Africa. So I believe our data will accumulate gradually, and we will see once we possess the final trial data.
Brian Goff
executiveOkay, many thanks, Victor, and I appreciate all of you joining us on this call today. It's obvious that right now is a really thrilling moment for Agios. We genuinely believe we are positioned to bring patients game-changing new treatments and to build substantial value for shareholders over the long term; so once more, thank you, and we hope to talk with you again before long.
Operator
operatorWe appreciate everyone joining us for today's call. That brings the program to an end. You're welcome to disconnect at this point. Have a wonderful day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.